Merck Sues Wyeth Over Patent for Infectious-Illness-Vaccine Tech
Health Law & Business News
Jan. 12, 2021, 4:26 PM
Merck & Co. asked a federal court to rule that its new pneumococcal vaccine, known as V114, won’t infringe three technology patents held by Pfizer’s Wyeth and used to protect against infectious diseases such as meningitis and pneumonia caused by the bacterium S. pneumoniae.
- The U.S. Food and Drug Administration earlier Tuesday accepted for priority review Merck’s biologics license application for V114
- Merck is seeking the court’s declaration that the patents are invalid and that Merck’s V114 wouldn’t infringe any valid claims, according to complaint filed Monday in federal court in Wilmington, Delaware
- Wyeth makes Prevnar 13 and Pfizer markets…
© 2021 The Bureau of National Affairs, Inc.
All Rights Reserved